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Treatment Options of Mature, Nodal T-Cell Lymphomas
Abstract
T-cell lymphomas represent only 10-15o/o of non-Hodgkin lymphomas. T
cell lymphomas are more agressive, heterogenous diseases and have worse
prognosis than B cell lymphomas. A number of new drugs are tested and
approved in the therapy of peripherial T cell tymphomas, which hopefully wilt
increase survival. cHoP and cHoP-like protocol are recommended for the
Íirst-line treatment, but it is efÍicacy alone only in ALK+ anaplastic large cell
lymphoma. Guidelines recommend front-line autologous hematopoetic stem cell
transplantation in the other most frequent subtypes. A number of new drugs
are tested and approved in the therapy of peripherial T cell lymphomas, eg.
romidepsin, pralatrexate, belinostat, brentuximab vedotin etc., which hopefully
will increase survival.
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AE: Adverse Event; AHSCT: Autologous Hemopoetic Stem Cell
Transplantation; AITL: Angioimmunoblastic T Cell Lymphoma;
ALCL:Anaplastic Large Cell Lymphoma; ALK: Anaplastic Lymphoma
Kinase; CHOP: Cyclophosphamide, Doxorubicin, Vincristine and
Prednisone; CHOEP: CHOP+etoposide; CR: Complete Remission;
EFS: Event-Free Survival; FDA: Food and Drug Administration; FFS:
Failure-Free Survival; HDAC: Histone Deacetylase; NCCN: National
Comprehensive Cancer Network; NHL: Non-Hodgkin Lymphoma;
OS: Overall Survival; PFS: Progression-Free Survival; PTCL-NOS:
Peripherial T-Cell Lymphoma Not Otherwise Specified; TCL: T Cell
Lymphoma; WHO: World Health Organization
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Non-Hodgkin lymphomas (NHLs) originate from T lymphocytes
and NK cells in l0-15%o of cases, while T-cell lymphomas (TCL)
represent approximately 25o/o of NHLs in Asian countries [l].
There are four main groups of T cell lymphomas in the WHO
classification: nodal, cxtranodal, cutan and lcukcmic group. Ncw
provosional entities of T cell lymphomas are introduced in the new
WHO 2016 classification, these changes mostly based on the result of
genomic studies [2]. Three subtypes are the most frequent in nodal
T cell lymphoma group: peripherial T-cell lymphoma not otherwise
specifiecl (PTCL-NOS), angioimmunoblastic T-cell lymphr-rma
(AITL) and systemic anaplastic large cell lymphoma (ALCL), which
may be positive or negative for anaplastic lymphoma kinase (ALK)
[2]. T cell lymphomas are more agressive, heterogenous diseases and
have worse prognosis than B cell lymphomas. Usually patients have
advanced stage disease and extranodal involvement at the time of
diagnosis. The minority of patients reach durable remissions or cure
after first-line treatment. Treatment of TCLs is unmet medical need
nowadays. A number of new drugs are tested and approved in the
therapy of PTCLs, which hopefully will increase survival.
Current first-line treatment options
Majority of PTCLs, except for ALK+ ALCL, has bad prognosis.
Thc S-ycar ovcrall survival (OS) for ALK+ ALCL, ALK-ALCL,
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PTCL-NOS and AITL was 707o, 49o/o, 32o/o and 32o/o and the S-year
failure-free survival (FFS) wa.s 600/o,360/o,20o/o and 18% [3]. The
frontline treatment in the most frequent PTCL types is combination
chemotherapy, usually anthracycline-based regimens, such as CHOp
(cyclophosphamide, doxorubicin, vincristine and prednisone), or
CHOP+etoposide (CHOEP) with autologous hemopoetic stem
cell transplantation (AHSCT) given as consolidation for high risk,
selected patients (except ALK+ ALCL) [4,5].
CHOP is the generally recommended and used protocol, but it
lras moderate eíficacy' A retrospective arralysis showed S-year OS
was only 37o/o in 2912 patients, who received CHOP or CHOP-like
chemotherapy [6]. The only exception was ALK+ and ALK - ALCL,
which has better survival, overall response rate (ORR) >75o/o and
5-year OS >607o [7]. PTCL-NOS patients who received anthracycline
in the initial treatment has no survival beneíit than patients who
didn't receive it [3].
There were a lot of trials to improve efficacy of the therapy.
Some studies used combination therapy eg. CHOP plus etopozid or
alemtuzumab, or another chemotherapy eg. ACVBP, VIP-rABDV,
alcmtuzumab, dcnilcukin diftitox t8l. VIP/ABVD (ctoposidc/
ifosfamide/ cisplatin-doxorubicin/ bleomycin/ vinblastine/
dacarbazine), CHOP/ESHAP did not improve the outcome [9-
l1l. Hyper-CVAD/MA (hyper-fractionated cyclophosphamide/
doxorubicin/ vincristine/ dexamethasone alternating with
methotrexate/ cytarabine) showed higher ORR and progression-free
survival (PFS), but not higher OS, than CHOP [12] in a retrospective
study, but this regimen associated with greater toxicity.
'lhe German High-Grade Lymphoma Study Group adrled
etoposide to CHOP (CHOEP) [13]. ORR was 82o/o and complete
remission) CR was 637o. Schmitz, et al. reported that CHOEP
treatment is more effective than CHOP in young patients'group, but
this treatment was no significantly better in >60 years old patients and
it was too toxic in this group [13].
The difference in event-free survival (EFS) for younger patients
and ALK+ ALCL treated with CHOP or CHOEP was significant (3-
year EFS for CHOEP patients 9l.2o/o vs. 57.Io/o for patients treated
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Table í: New Íirst line treament options.
First line treatment
cHoEP [13]
CHOP+romidepsin [22]
romidepsin-CHOP [54]
Brentuximab vedotin-CH P [47]
bortezomib-CHOP [50]
everolimus-CHOP [55]
alemtuzumab-CHOP [57]
pralatrexate-CEOP [58]
(ORR: overall response rate, CR: complete response)
Table 2: New salvage treament options.
Salvage treatment
pralatrexate [20]
romidepsin [21]
belinostat Í23,24|
brentuximab vedotin [25]
bendamustin [28]
mogamulizumab [29]
mogamulizumab [30]
zanolimumab [31]
lenalidomide [32]
lenalidomide [33]
alisertib [35]
crizotinib [37,38]
gemcitabin [39]
bortezomib [40]
everolimus [44]
duvelisib [45]
nivolumab [46]
bortezomib-gemcitabin [51 ]
gemcitabin-romidepsin [52]
gemcitabin-dexamethason-cisplatin [53]
(ORR: overall response rate, CR: complete response)
ORR
82o/o
69%
78o/o
100o/o
760/o
90%
680/o
70o/o
ORR CR
29o/o 11o/o
38o/o 18o/o
260/o 11o/o
86% 57o/o
50o/o 28o/o
5Oo/o 31o/o
35o/o 14o/o
24o/o 10o/o
30o/o 0o/o
22o/o 11o/o
50o/o
91o/o 27o/o
55o/o 30o/o
670/o 'l3o/o
44o/o 60/o
47o/o 13o/o
17o/o
360/o 27o/o
3Oo/o 15o/o
72o/o 48o/o
CR
630/o
51o/o
660/o
88o/o
65%
57o/o
37o/o
52o/o
grade 3/4 toxicities
neutropenia 890/o
febrile neutropenia 31 %
neutropenia 41%
neutropenia 80%
neutropenia 70olo
anáemia27 o/o
grade 3/4 toxicities
thrombocytopenia 33%
thrombocytopenia 13%
neutropenia 21olo
neutropenia 30o/o
lymphopenia 74%
lymphopenia 73%
lymphopenia'10%
th rombocytop enia 42o/o
throm bocytop enia 2Oo/o
neutropenia 637o
neutropenia 13% (only grade3)
anaemia 25o/o
comment
only cD30+PTCL
all AITL were in CR
only CD52+PTCL
comment
AITL had fewer response
AITL had ORR 46%
only CCR4+ TCL
only CCR4+ TCL
only CD4+ TCL
with CHOP, p = 0.012), a statistically not significant difference was
seen in the remaining patients when ALK+ ALCL was excluded (3-
year EFS for CHOEP patients 60.70/o vs. 48.37o for patients treated
wirh cHoP,P = 0.057) [13].
CHOEP was associated with improved PFS in patients younger
than 60 years in a Swedish analyzis also [14].
Autologous transplantation is recommended ALK-ALCL patients
in first-linc treatmcnt, but not in ALK+ALCL patients [51. D'Amorc,
et al. showed 5-year OS70o/o and PFS 610/oLnALK-ALCL patients who
were treated 6 cycles CHOEP followed by AHSCT, if they were in CR/
CRu or PR [15]. AHSCT produces better S-year OS in ALK+ than
AlK-patients (827o versus 54yo) Í16).
Based on these results National Comprehensive Cancer Network
(NCCN) guidelines recommend CHOP-2l or CHOEP-21 regimens
only ALK+ ALCL
ORR:40 % in PTCL patients
thrompocytopenia 60%
neutropenia 'l60lo
as the first-line therapy in AlK-positive ALCL and clinical trials and/
or frontline AHSCT for first-line therapy in all other subtypes [5].
New therapeutic options
Only half of the TCL patients reached complete remission (CR)
aftcr first line trcatment and only half of thcsc paticnts havc durable
remission [17]. Majority of T-cell lymphoma patients (about 707o)
have rcfractory disease or rclapsc aftcr thc first line treatment [41.
Relapsed/refractory (R/R) PTCL patients'overall survival (OS), who
did not undergo AHSCT, 5.5 months only [18].
There is no uniform recommendation to the optimal treatment
relapsed and refractory patients. A lot of clinical trials was conducted
and these showed various efficary (Table 1,2). Three new drugs
was approved by the FDA in the therapy of R/R PTCL patients,
pralatrexate, romidepsin and belinostat.
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FDA approved new drugs
Pralatrexate: Pralatrexate, an antimetabolite drug, which
selectively enters cells through reduced folate carrier type l, FDA
approved this drug for the treatment of patients with R/R PTCL in
2009. O'Connor, et al. conducted a dose/schedule finding study in
R/Rlymphomas [19]. ORRs were l0o/o and54o/o in patients with B-cell
and T-cell lymphomas respectively. All eight patients who achieved
CR had T-cell lymphoma. PROPEL was the first international
prospective study of novel therapeutic agents in patients with PTCL
[20]. One hundred and nine heavily pretreated PTCL patients recevied
the drug, ORR and CR/CRu (CR uncorflrmed) rates were 29o/o and
117o. Patients with AITL had fewer responses (l out of 13 patients)
than other subtypes. Patients who received only CHOP before
pralatrexate, the ORR was 47o/o and the CR rate was 307o, suggesting
that the response rate might be higher if pralatrexate is used earlier,
not in heavily pretreated patients. Grade 3/4 adverse events (AEs)
were thro mb ocytopeni a (3 3o/o), m ucos itis (22o/o), neutrop en i a (22o/o)
and anemia (I8o/o) [20].
Romidepsin: Romidepsin is a new potent class I selective histone
deacetylase (HDAC) inhibitor, which was was approved by the FDA
in 20ll for the treatment of PTCL in patients who hatl received > I
prior therapies. A phase II trial used romidepsin in 47 PTcLpatients
with various histologic subtypes [21]. Among 45 evaluable patients
in this study ORR was 387o and 18% hacl CR. 'lhe most common AEs
were nausea (517o), thrombocytopenia (47o/o), leukopenia (47o/o),
granulocytopenia (4570), fatigue (40yo) and anemia (4OVo) [21]. One
hundred and thirty patients were treated with romidepsin in another
phase II trial. Most patients had PTCL-NOS (n=69), AITL (n=27),
or AlK-negative ALCL (n=21). The ORR was25%o and l5Zo had CR.
The most common grade 314 AEs were thrombocytopenia (24o/o),
neutropenia (20Vo) and infections (197o).
Single-arm, phase Ib/II study used CHOP plus romidepsin as
first line treatment in 37 PTCL patients. Among 35 evaluable patients
the ORR was 9% and CR was 5l%. Three patients had early cardiac
events, including two myocardial infarctions and one acute cardiac
failure. The most frequent serious AEs were febrile neutropenia
147o, physical health deterioration and lung infection ll7o. Grade
3/4 neutropenia were detected in 897o of patients and grade 3/4
thrombocytopenia in 7 8o/o [22].
Belinostat: Belinostat is a pan-HDAC inhibitor, which was
investigated in R/R PTCL patients in the BELIEF trial. One hundred
and twenty-nine patients received belinostat, among the 120 evaluable
patients, the ORR was 260/o, CR was 117o. ORR was the best, 46Zo in
AITL. the most common grade 3i4 AEs were thrombocytopenia
(l37o), neutropenia (I3%o) and anemia (10o/o) Í23,24]. Based on the
results of this study FDA approval belinostat in 2OI4 for treatment of
R/R PTCL patients.
Other new therapeutic options
Monotherapy: Brentuximab vedotin: Brentuximab vedotin (BV)
is an immunoconjugatc of an antitubulin agcnt and a CD30-spccific
immunoglobulin G I monoclonal antibody. Fifty cight ALCL paticnts
were treated with BV in a phase II study, ORR was 86yo and CR was
57o/o. The most common AEs wcrc pcriphcral scnsory ncuropathy
(4lo/o), nausea (40o/o), fatigue (387o) and pyrexia (34%o). Based on the
results of this study, the FDA and European Medicines Agency, in
2011 and 2012, approved the use of BV for patients with systemic
ALCL after failure of > I multi-agent chemotherapy regimen [25].
Another phase II trial of BV in 35 patients showed ORR of 4l7o
and no correlation between CD30 expression per central review
and response was observed [26]. Grade 3/4 adverse events were
neutropenia (2lo/o), thrombocytopenia (I 4%o) and peripheral sensory
neuropathy (Izvo) Í27 ].
Bendamustine: Bendamustine is an alkylating agent with
antimetabolite effect. In the BENTLY trial, 60 patients with CTCL
and PTCL (mainly AITL and PTCL-NOS) were treated with
bendamustine. The ORR was 507o and CR was 287o. The most
frequent grade 314 AEs were neutropenia (307o), thrombocytopenia
(2aVo) and infections (207o) [28].
Mogamulizumab: Mogamulizumab is an anti- CC chemokine
receptor 4 (CCR4) monoclonal antibody. Mogamulizumab depletes
CCR4-positive regulatory T cells and help to enhance antitumor
activity. Twenty-seven relapsed agressive CCR4-positive T cell
lymphoma patients received mogalizumab in a phase II study. ORR
was 507o and CR was 317o. 'lhe most common grade 3/4 AL,s were
lymphopen ia (7 4o/o),leukocytopenia (307o), thrombocytopenia (L9o/o),
neutropenia (19%o) and rash (19%o) [29]. Another phase II study of
mogamulizumab at the same dose in 38 patients, of whom 37 were
evaluable with relapsed CCR4-positive PTCL or CTCL, reported an
ORR of 35%, includingL4o/o with a CR. The most common grade 3/4
AEs were lymphopenia (73o/o) and neutropenia (l9Zo) also [30].
Zanolimumab: Zanolimumab is an anti-CD4 monoclonal
antibody. Twenty-one R/R CD4+ PTCL patients were treated with
zanolimumab ORR was 24o/o and CR was 107o. Grade 3 AEs were
lymphopenia (107o), infusion-related AEs (107o) and arthralgia (5yo)
[31].
Lenalidomide Lenalidomide is an immunomodulatory drug
which inhibits vascular endothelial growth factor (VEGF), activation
of natural killer cells and T lymphocytes and modulates various
cytokines such as tumor necrosis factor-o, interleukin-12 and
intcrfcron-y. A phasc II study uscd lcnalidomid in 24 paticnts. Among
the 23 evaluable patients, ORR was 307o, but there are no patients in
CR. Thc most common gradc 3/4 AEs wcre thrombocytopcnia (42o/o),
neutropenia (2lo/o), dyspnea (L7o/o), febrile neutropenia (l7Zo), pain
(I7o/o) and pneumonitis (l7Vo) [32]. EXPECT was an phase II study
which included 54 parients with R/R PTCL. ORR was 22yo, CR/CRu
was 117o. Most common grade 3/4 AEs were thrombocytopenia
(20o/o), gastrointestinal disorders (l7o/o), neutropenia (15Yo) and
infections ( 15olo) [33].
Alisertib: Aurora A kinase (AAK) is a mitotic kinase which is
upregulated in PTCL [34]. Alisertib is an oral selective AAK inhibitor,
a phase II trial evaluated its efficacy in refractory T-cell and B-cell
lymphomas. ORR was 50%o in eight PTCL patients. Grade 3/4 AEs were
neutropenia 637o, leukopenia 54o/o, anemia 357o, thrombocytopenia
33o/o and stomatitis l5% [351. Thirty-scvcn R/R PTCL paticnts wcrc
treated in another phase II intergroup trial (SWOG ll08). Among
ORR was 307o Grade 3/4 AEs were neutro penia (32o/o), anemia (30o/o),
thrombocytopenia (24o/o), febrile neutropeni a (I4o/o),mucositis ( I l7o)
and rash (57o). Based on these results, a randomized phase III trial of
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alisertib versus the investigator's choice (pralatrexate or gemcitabin
monotherapy) was designed for patients with relapsed PTCL, but
study was closed earlier due to alisertib was not more effective than
other treatments [ 17,36].
Crizotinib: Crizotinib is an oral small-molecule tyrosine kinase
inhibitor of ALK, which has been FDA approved for the treatment of
lung cancer. Eleven refractory ALK+ lymphoma patients (9 ALCL)
receiverl crizotinib (JRR was 917o, CR was 27%o.'Ihere were no grade
3/4 toxicity [37,38]. A clinical trial is ongoing in ALK+ ALCL patients
with use of crizotinib.
Gemcitabin: Gemcitabin is a nucleoside analog, which inhibits
DNA replication and repair. Other nucleoside analogs are pentostatin,
cladribinc, fludarabinc, clofarabinc, forodcsinc and nclarabinc. Thcsc
agents are cytotoxic to both proliferating and non-proliferating
cclls. Gcmcitabinc, cladribinc and fludarabinc havc shown cfficacy
in PTCL and gcmcitabinc is thc mosi cffcctivc in PTCL. NCCN
guidelines recommends as second-line therapy for patients with
relapsed PTCL [5]. Twenty R/R PTCL-NOS patients were treated
with gemcitabine [39]. ORR was 557o and CR was 30%.'lhere was no
grade 3 I 4 hematological toxicity.
Bortezomib: Bortez.omib is a proteasome inhibitor. Fifteen
relapsed CTCL or PTCL patients got in a phase II trial. ORR
was 670/o and CR was l3%. The most common grade 3 toxicities
were neutropenia (L3o/o), thrombocytopenia (l3Vo) and sensory
ncuropathy (13V,) and thcrc was no gradc 4 toxicity [a01. Thc NCCN
has recommended bortezomib as a second-line therapy for patients
without intention to proceed to transplantation [5].
AG-2212 Isocitrate dehydrogenase 2 (lDH2) mutations have
been identified in solid tumors and hematologic malignancies eg.
glioblastoma, acute myeloid leukemia and myelodyplastic syndromes.
AML and MDS patients reached 567o ORR with IDH2 inhibitor (AG-
221)in a phase I study [41]. IDH2 mutations are frequent in AITL
(20-450Á) so IDH2 inhibitor can be effective in this lymphoma type
Í42,43).
Everolimus: The mTOR pathway is responsible for TCL
proliferation. Everolimus is a mTORCI inhibitor. Sixteen relapsed
TCL were treated with everolimus in a phase II study. The ORR was
44o/o and CR was 67o. Grade 3/4 AEs were anaemia (25o/o),leukopenia
(I9%o) and thrombocytopenia L3vo) Íaa).
Duvelisib: Duvelisib (IPI-145) is an oral phosphatidilinozitol
3-kinase inhibitor (PI3K). Sixteen PTCL patients received duvelisib.
oRR was 47o/o and CR was I3Vo Í45).
Nivolumab: Programmed death-1 (PD-l) immune checkpoint
pathway help tumour cells to avoid immune surveillance. Nivolumab
is a PD-1 inhibitor, which is approved by FDA in the treatment of
Hodgkin lymphoma. The activity of nivolumab in other lymphoid
malignancies also has been presented [a6]. Responses also were seen
in 23 patients with TCL, with superior response seen in patients with
PTCL. Thc ORR for paticnts with TCL was l7o/o, thcrc was no CR.
Thc ORR in paticnts with PTCL was 40% and was 15% in thosc with
cutaneous T cell lymphoma [46].
New combination therapy: Brentuximab vedotin-CHP: BV and
CHP combination therapy was examined in a phase I open-label
study as frontline treatment in patients with CD3O-positive PTCL.
Twenty-six patients were treated, all of them achieved an objective
response and CR was 887o. Grade 3/4 AEs were febrile neutropenia
(317o), neutropenia (23o/o), anemia (15olo) and pulmonary embolism
(Lzyo) Í47]. 
^ 
randomized phase III trial is ongoing, comparing BV
and CHP combination with CHOP alone.
Alemtuzumab-CHO(E)P: Alemtuzumab is an anti-CD52
monoclonal antibody that causes depletion of CD4 and CD8 T
cells as well as B cells. Alemtuzumab combined with CHO(E)P was
investigated 29 patients as consolidation therapy in a phase II trial,
CR rate was 58.57o. Grade 3/4 toxicities were infections (14olo) [48].
Another phase II study investigated combination of alemtuzumab,
íludarabine, ryclophosphamide and tloxorubicin irr 27 PTCLpatients'
íirst line treatment and l1 R/R PTCL patients. ORR was 61%, with a
CR of 39%. 'the most frequent grade 3/4 toxicities were leukopenia
(95Yo) and thrombocytopenia (587o). Cytomegalovirus (CMV)
reactivation was detected in 12 patients, but only two had CMV
disease. Treatment-related deaths occurred in six newly diagnosed
and one R/R patient [49]. Alemtuzumab-based therapy was active in
PTCL but was associated with significant toxicity.
Bortezomib-CHOP: Forty six patients were treated with
bortczomib plus CHOP as firstlinc trcatmcnt. ORR was 760/o and
CR was 657o. Outcome was similar to CHOP alone. Grade 3/4
neutropenia was in 4lo/o oÍ patients, febrile neutropenia in 307o and
thrombocytopenia in 1l7o [50].
Bortezomib-gemcitabin: Bortezomib with gemcitabin was used
in 16 R/R PTCL patients in a phase I/lI ORR was 367o and CR was
27%o [5r].
Gemcitabin-romidepsin: A phase II trial was conducted
in R/R PTCL. Twenty patients were treated with combination
of gemcitabine plus romidepsin (GEMRO regimen). The ORR was
30o/o,3 patients had CR. Two-year OS was 507o and PFS 11.27o.
Sixty percent of the patients had grade >3 thrombocytopenia, half
of the patients had neutropenia. The majority of non-hematological
toxicities were mild and transient. There was no treatment-related
death or toxicity which led to treatment interruption [52].
Gemcitabin-dexamethason-cisplatin: CISL trial investigated
GDP (gemcitabin-dexamethason-cisplatin) protocoll in 25 R/R PTCL
patients. ORR was 72o/o and CR was 487o. Grade 3/4 neutropenia
(l6yo) and thrombocytopenia (I3%o) was occurred [53].
Romidepsín-CHoP: Romidepsin plus CHoP was investigated
in a phase Ib/II study in first line treatment of 14 PTCL patients. ORR
was78o/o, CR was 660/o Í54].
Everolimus-CHOP: A phasc II study invcstigatcd thc cfficacy
of cvcrolimus plus CHOP thcrapy for first-line trcatmcnt in PTCL.
Thirty paticnts wcrc trcatcd, ORR was 90%, CR was 57%. Thc CR
ratc was diffcrcnt among subtlpcs, all AITL paticnts had CR whcrcas
PTCL-NOS and AlK-negative ALCL patients showed 630/o and 29o/o
CR. Eighty percent of patients suffered grade 314 neutropenia and
607o of patients had grade 3/4 thrombocytopenia [55].
Pirarubicin-COP: Pirarubicin is a derivative of doxorubicin,
which is less cardiotoxici than the doxorubicin. A retrospective study
analysed 56 patients with PTCL-NOS who had received pirarubicin
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Figure í: Treatment options (other than clinical trials) in mature, nodal T cell
lymphoma.
plus COP or CHOP treatment. Twenty-nine patients
received pirarubicin and COP and 27 received CHOP. CR was 52%
in both groups and there were no significant differences in 3-year OS
and PFS rates. Pirarubicin and COP led significantly better prognosis
in low risk patients [56].
Alemtuzumab-CHOP: Phase I trial was conducted in 20 CD52-
positive PTCL patients. ORR and CR were 687o and 37o/o. Grade 314
neutropenia were in 70o/o oÍ the patients and thrombocytopenia 207o
Í57).
Pralatrexate-CEOP: First-line cyclophosphamide, etoposide,
vincristine and prednisone (CEOP) alternated with pralatrexate
treatment was used in a phase 2 study. Thirty-three PTCL patients
were treated with this protocol. ORR was 70o/o and 52o/o oí the patients
had CR. Thc 2-ycar OS and PFS wcrc 60% and 39%, so this ncw
combination did not improve outcomes compared to historical data
using CHOP. Thc most frcqucnt gradc 3/4 AEs wcrc anacm ta in 27o/o
of patients and febrile neutropenia in 18o/o of patients [58].
Pixantrone-etoposid-bendamustin: Pixantrone is an analogue
of mitoxantrone, but it has fewer cardiotoxic effect. A phase l/2 study
(pixantrone, etoposide and bendamustin) is ongoing in B- and T-cell
lymphoma patients.
NCCN recommends in second-line therapy as single-agent
treatment: clinical trials, belinostat, romidepsin, pralatrexat and
brentuximab vedotin in CD30+ PTCL, or combination therapy (eg.
DHAP, ESHAP, ICE). Other alternative regimens (eg. bendamustin,
gemcitabin,lenalidomid) can also be used ( Figure l)[5].
(lqrnclnsiorr
TCLs are aggressive, heterogenous, rare lyrnphoma qrpes. There
are a lot of subtypes in the WHO 2016 classification, but relatively
few patients in Europe and USA, so the diagnosis is usually difficult.
CHO(E)P chemotherapy is usually recommended for the first-
line treatment, but it is not effective in majority of PTCLs (except
ALK+ALCL). Frontline AHSCT is suggested for all other subtypes.
Remission can be reached mostly, if patients undergo AHSCT in CR/
CRu, but it is difficult due to the inadequate firstline chemotherapy
possibilities, so guidelines recommend patient's treatment in clinical
trials. Use of PET/CT is also suggested in the staging and in resPonse
assessment. AHSCT can be more successfull if PET/CT show CR after
chemotherapy. Prognosis is very poor in relapsed patients. Several
drugs were tested in the treatment of TCLs in last years, but roaring
succes was not reached. Long-term remission is the basis of the cure,
so better efficiency therapy must be found.
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